Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D M Fletcher

Showing results (291-300 of 311) with videos related to

Pageof 32
Sort By:
Archives of Pathology & Laboratory Medicine|April 7, 2010
Protocol for the examination of specimens from patients with tumors of soft tissueBrian P Rubin, Kumarasen Cooper, Christopher D M Fletcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Current Biology : CB|February 8, 2005
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanomaE Elizabeth Patton, Hans R Widlund, Jeffery L Kutok, et al.
Histopathology|December 4, 2022
Datasets for the reporting of primary tumour in bone: recommendations from the International Collaboration on Cancer Reporting (ICCR)Judith V M G Bovée, Fleur Webster, Fernanda Amary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2023
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Histopathology|March 17, 2023
Large cell calcifying Sertoli cell tumour: molecular and immunohistochemical assessment of a series comprising non-metastasising and metastasising neoplasmsSanhong Yu, Lynette M Sholl, Stephanie Siegmund, et al.
The Journal of Pathology|November 6, 2009
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumoursSubbaya Subramanian, Venugopal Thayanithy, Robert B West, et al.
Histopathology|October 13, 2022
Myoid gonadal stromal tumours are characterised by recurrent chromosome-level copy number gains: molecular assessment of a multi-institutional seriesKatrina Collins, Lynette M Sholl, Stephanie Siegmund, et al.
Pageof 32

Showing results (291-300 of 311) with videos related to

Sort By:
Pageof 32
Archives of Pathology & Laboratory Medicine|April 7, 2010
Protocol for the examination of specimens from patients with tumors of soft tissueBrian P Rubin, Kumarasen Cooper, Christopher D M Fletcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Current Biology : CB|February 8, 2005
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanomaE Elizabeth Patton, Hans R Widlund, Jeffery L Kutok, et al.
Histopathology|December 4, 2022
Datasets for the reporting of primary tumour in bone: recommendations from the International Collaboration on Cancer Reporting (ICCR)Judith V M G Bovée, Fleur Webster, Fernanda Amary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2023
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Histopathology|March 17, 2023
Large cell calcifying Sertoli cell tumour: molecular and immunohistochemical assessment of a series comprising non-metastasising and metastasising neoplasmsSanhong Yu, Lynette M Sholl, Stephanie Siegmund, et al.
The Journal of Pathology|November 6, 2009
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumoursSubbaya Subramanian, Venugopal Thayanithy, Robert B West, et al.
Histopathology|October 13, 2022
Myoid gonadal stromal tumours are characterised by recurrent chromosome-level copy number gains: molecular assessment of a multi-institutional seriesKatrina Collins, Lynette M Sholl, Stephanie Siegmund, et al.
Pageof 32